Physician
Bethany Medical Center
Bethany Medical Center was paid $5.13M by Medicaid between May 2019 and Dec 2024, across 94 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 33% of everything it billed.
33Billing provider infoBETHANY MEDICAL CENTER
WINSTON SALEM, NC 27106
WINSTON SALEM, NC 27106
33aNPI1710453550assigned 10/19/2018
33bProvider typeDermatology Physician
28Total paid$5.13M
24GClaims261,584
24DCodes billed94
24AFirst – last monthMay 2019 – Dec 2024
Compared with peers
Next to other Dermatology Physician providers in North Carolina
Rank by total paid#4 of 54
Median peer was paid$176K
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PETERS, LENIN controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,845 | $93K | |
| 2020 | 12,499 | $499K | |
| 2021 | 19,150 | $674K | |
| 2022 | 44,205 | $1.01M | |
| 2023 | 65,611 | $1.17M | |
| 2024incomplete | 117,274 | $1.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33% | 31,376 | 24,431 | $1.70M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 17% | 13,751 | 10,875 | $882K |
| 99199 | Unlisted special service, procedure or report | 8.6% | 63,157 | 33,496 | $443K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 8.1% | 4,054 | 3,068 | $414K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.6% | 10,243 | 8,331 | $391K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 7.2% | 5,814 | 4,982 | $372K |
| 83970 | 1.7% | 1,956 | 1,646 | $85K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 2,140 | 1,795 | $67K |
| 99406 | 1.3% | 9,058 | 6,947 | $64K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 889 | 646 | $57K |
| 90792 | Psychiatric diagnostic evaluation with medical services | 1.1% | 815 | 582 | $56K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 493 | 435 | $37K |
82 more codes
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 458 | $36K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,062 | $33K |
| 86769 | <1% | 818 | $32K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,299 | $30K |
| 94375 | <1% | 1,668 | $29K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 511 | $28K |
| 99443 | <1% | 415 | $27K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,703 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,372 | $27K |
| 80061 | Lipid panel | <1% | 1,754 | $25K |
| 81025 | <1% | 3,631 | $22K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,134 | $19K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 887 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,959 | $18K |
| 82607 | <1% | 1,154 | $18K | |
| 82746 | <1% | 1,130 | $17K | |
| 82728 | <1% | 1,165 | $16K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,620 | $14K |
| 84480 | <1% | 971 | $14K | |
| 93000 | <1% | 1,224 | $13K | |
| 99442 | <1% | 350 | $12K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 716 | $11K |
| 83550 | <1% | 1,163 | $10K | |
| 99401 | <1% | 410 | $9K | |
| 84439 | <1% | 991 | $9K | |
| 80050 | General health panel | <1% | 682 | $7K |
| 86703 | <1% | 409 | $5K | |
| 83540 | <1% | 579 | $4K | |
| 72100 | <1% | 236 | $4K | |
| 82962 | <1% | 2,316 | $4K | |
| 86803 | <1% | 218 | $3K | |
| 17110 | <1% | 48 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 290 | $2K |
| 87340 | <1% | 230 | $2K | |
| 83735 | <1% | 245 | $2K | |
| 81002 | <1% | 1,500 | $1K | |
| 90756 | <1% | 104 | $1K | |
| 90688 | <1% | 111 | $995.95 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 355 | $767.40 |
| 90661 | <1% | 44 | $653.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $615.72 |
| 72050 | <1% | 19 | $400.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 396 | $292.12 |
| 72070 | <1% | 14 | $268.23 | |
| 86431 | <1% | 41 | $267.05 | |
| G2011 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes | <1% | 93 | $219.38 |
| 82044 | <1% | 132 | $206.72 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 73 | $188.14 |
| 3044F | <1% | 1,793 | $160.00 | |
| 96146 | <1% | 204 | $154.85 | |
| 84550 | <1% | 29 | $145.67 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 284 | $96.38 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 169 | $96.14 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 346 | $52.41 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 21 | $34.54 |
| 3008F | <1% | 27,162 | $33.97 | |
| 96160 | <1% | 67 | $26.51 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 825 | $3.07 |
| 4004F | 0% | 4,786 | $0.00 | |
| 3078F | 0% | 11,726 | $0.00 | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 0% | 166 | $0.00 |
| 3077F | 0% | 1,325 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 142 | $0.00 |
| 1159F | 0% | 133 | $0.00 | |
| 80348 | 0% | 16 | $0.00 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 157 | $0.00 |
| 92546 | 0% | 22 | $0.00 | |
| 92547 | 0% | 16 | $0.00 | |
| 3079F | 0% | 3,057 | $0.00 | |
| 3074F | 0% | 11,877 | $0.00 | |
| 3048F | 0% | 597 | $0.00 | |
| 3080F | 0% | 151 | $0.00 | |
| G0443 | Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes | 0% | 138 | $0.00 |
| 3075F | 0% | 1,227 | $0.00 | |
| G8839 | Sleep apnea symptoms assessed, including presence or absence of snoring and daytime sleepiness | 0% | 110 | $0.00 |
| 1125F | 0% | 972 | $0.00 | |
| 3049F | 0% | 128 | $0.00 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 0% | 188 | $0.00 |
| 4010F | 0% | 36 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 132 | $0.00 |
| 1170F | 0% | 100 | $0.00 | |
| 3060F | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETERS, LENIN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Bethany Medical Center | High Point, NC | $18.31M |
| Bethany Medical Center | Greensboro, NC | $7.28M |
| Bethany Medical Center | Greensboro, NC | $5.72M |
| Bethany Medical Center | Winston Salem, NC | $4.74M |
| Bethany Medical Center | High Point, NC | $3.77M |
| Bethany Medical Center | Kernersville, NC | $2.29M |
| Bethany Medical Center | Greensboro, NC | $1.70M |
| Bethany Medical Center | Kernersville, NC | $1.62M |
| Bethany Medical Center | Mount Airy, NC | $1.50M |
| Bethany Medical Center, PA | High Point, NC | $1.47M |
| Bethany Medical Center PA | High Point, NC | $1.25M |
| Bethany Medical Center PA | High Point, NC | $1.13M |
| Bethany Medical Center, PA | High Point, NC | $645K |
| Bethany Medical Center | High Point, NC | $524K |
| LJP Anesthesia Services, PLLC | High Point, NC | $198K |
| Bethany Medical Center | High Point, NC | $88K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.